Quarter Period Consolidated Statement Of Comprehensive Income

Daito Pharmaceutical Co., Ltd. - Filing #7362493

Concept 2023-06-01 to
2023-11-30
2022-06-01 to
2022-11-30
Quarter period consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
1,494,000,000 JPY
1,724,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
76,000,000 JPY
305,000,000 JPY
Foreign currency translation adjustment
61,000,000 JPY
96,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-50,000,000 JPY
38,000,000 JPY
Other comprehensive income
87,000,000 JPY
440,000,000 JPY
Comprehensive income
1,581,000,000 JPY
2,164,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
1,622,000,000 JPY
2,176,000,000 JPY
Comprehensive income attributable to non-controlling interests
-40,000,000 JPY
-11,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.